Welcome to our dedicated page for GSK plc SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc has appointed Roy Jakobs to its Board as an independent Non-Executive Director, effective 13 July 2026. He is currently Chief Executive Officer of Royal Philips, a global health technology company with 2025 sales of 17.8 billion EUR and 65,000 employees.
GSK’s Board determined that Jakobs meets independence criteria under the UK Corporate Governance Code. He will receive the standard annual Non-Executive Director fee of £122,258 and is required to build a holding of GSK shares equal to two times this fee, in line with the shareholder-approved Non-Executive Director remuneration policy.
GSK plc reported its total voting rights and share capital as of 30 June 2026. The company had 4,316,276,428 issued ordinary shares of 31¼ pence each, including 270,881,064 shares held in treasury.
This leaves 4,045,395,364 voting rights, which shareholders can use as the reference figure when deciding whether they must disclose holdings or changes under the UK Financial Conduct Authority’s transparency rules.
GSK plc reports that it has repurchased ordinary shares under its existing buyback programme, using Citigroup Global Markets Limited as broker, and has now completed the buyback of up to £2 billion announced on 24 February 2025.
Between 22 and 26 June 2026, GSK bought 1,054,653 ordinary shares of 31¼ pence each at volume-weighted average prices between 1,919.89 and 1,967.46 GBp per share. Since 24 February 2025, it has purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion. After these purchases, GSK holds 270,881,064 shares in treasury and has 4,045,395,364 ordinary shares in issue, so total voting rights are 4,045,395,364 and 6.70 per cent of voting rights are now attributable to treasury shares.
GSK plc reports a regulatory notification of major holdings after a shareholder’s stake fell below a key threshold. The holder’s total voting rights decreased from 5.010000% to 4.960000%, representing 201,065,668 voting rights in GSK.
The position is split between ordinary shares and American Depositary Receipts (ADRs). Ordinary shares carry 88,816,040 indirect voting rights, equal to 2.190000% of voting rights, while ADRs carry 112,249,628 indirect voting rights, equal to 2.770000% of voting rights. No additional voting rights are held through financial instruments.
GSK plc reports a change in a major shareholding, as a notification under the TR-1 regime shows the holder’s total voting interest reaching 5.010000% of voting rights in the company. This corresponds to 203,320,168 voting rights in total, up from a previously reported position of 4.930000%.
The interest is held entirely through shares rather than derivative or other financial instruments. It includes voting rights linked to ordinary shares with ISIN GB00BN7SWP63 and to ADRs with ISIN US37733W2044. No additional voting rights are reported through financial instruments in this notification.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through a company savings plan. The transaction involved 9.4103 ADS at a price of $50.7400 per ADS on the New York Stock Exchange on 2026-06-22, within her GSK Executive Supplemental Savings Plan account.
GSK plc has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. The offer is being made through Harmony Row Acquisition Co., a wholly owned subsidiary of GlaxoSmithKline LLC, under an Agreement and Plan of Merger dated June 9, 2026.
After the tender offer is completed and conditions are met, Harmony Row Acquisition Co. will merge into Nuvalent under Section 251(h) of the Delaware General Corporation Law, making Nuvalent a wholly owned subsidiary of GSK LLC. Nuvalent’s board has recommended that stockholders accept the offer. The offer and withdrawal rights are scheduled to expire at one minute after 11:59 p.m. Eastern Time on July 14, 2026, unless extended or terminated.
GSK plc reported a series of open‑market share purchases by its board leaders in June 2026. Non‑Executive Chair Sir Jonathan Symonds bought 1,550 ordinary shares at £19.3524 each on the London Stock Exchange on 2026-06-19. On 2026-06-22, several Independent Non‑Executive Directors, including Elizabeth McKee Anderson, Charles Bancroft, Anne Beal, Hal Dietz, Jeannie Lee and Vishal Sikka, purchased American Depositary Shares on the New York Stock Exchange at a price of $50.6908 per ADS in individual amounts ranging from 667 to 1,855 ADS.
GSK plc reports purchases of its own ordinary shares between 15 and 19 June 2026 under its existing share buyback programme, executed through Citigroup Global Markets Limited. Daily purchases ranged from 209,874 to 245,840 shares, at volume-weighted average prices between 1,934.67 and 1,971.11 GBp per share.
The purchased shares will be held as treasury shares. Since 11 May 2026, GSK has bought 8,448,125 ordinary shares. After these transactions, it holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the total number of voting rights.
The company states that, following these purchases, 6.67 per cent of voting rights are attributable to ordinary shares held in treasury, which shareholders can use as the denominator for disclosure calculations under UK transparency rules.
GSK reports that the US FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options.
The approval is based on the phase III PIVOT-PO trial, where oral tebipenem pivoxil 600 mg achieved a 58.5% overall success rate versus 60.2% for intravenous imipenem-cilastatin 500 mg, meeting the preset non-inferiority margin. Safety was generally similar to comparator carbapenems, with mostly mild to moderate diarrhoea and headache.
cUTIs account for more than 3 million cases annually in the US and over $6 billion in healthcare costs, with treatment failure affecting up to 34% of patients. Tebipenem pivoxil is anticipated to be available to US patients by the end of 2026 and extends GSK’s anti-infectives portfolio under its collaboration with Spero Therapeutics.